Sign in
Taking people in United StatesPhase 1

Tests dorzagliatin for blood sugar problems in people with cystic fibrosis

Tests dorzagliatin against placebo in adults with cystic fibrosis and abnormal glucose tolerance.

Key facts

Who runs it
Michael R. Rickels, MD, MS
Where
Philadelphia, United StatesSee the 2 sites
Trial code
Registry title
Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis
Status
Recruiting
Phase
Phase 1
People taking part
15 people, planned
Started
21 Oct 2025
Expected to end
Jul 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Dorzagliatin
  • Placebo
Record updated
31 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cystic fibrosis who need pancreatic enzyme replacement and have abnormal glucose tolerance. It tests dorzagliatin against placebo for 7 days each.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Confirmed cystic fibrosis (positive sweat test or CFTR mutation test) with pancreatic insufficiency and abnormal glucose tolerance or cystic fibrosis-related diabetes. With fasting high blood sugar, HbA1c must be 8% (64 mmol/mol) or lower and C-peptide at least 1.2 ng/mL.
Earlier treatment
Cannot have changed CFTR modulator therapy in the last 3 months. Cannot have used CYP3A4 inhibitors or inducers, or herbal remedies such as St. John's Wort within 14 days before dosing.
Biomarker or test result
Positive sweat test or CFTR mutation; abnormal glucose tolerance on an oral glucose tolerance test, or diagnosed cystic fibrosis-related diabetes.

Main reasons for not taking part

  • Diabetes not caused by cystic fibrosis, such as type 1 diabetes
  • Pregnancy or breastfeeding
  • Lung flare-up needing IV antibiotics or systemic glucocorticoids in the last 4 weeks
  • Pancreatitis with symptoms in the last year
  • Earlier lung, liver or other solid organ transplant

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged ≥18 years on date of consent
  • Confirmed diagnosis of CF, defined by positive sweat test or CFTR mutation analysis according to CFF diagnostic criteria
  • Pancreatic insufficiency defined by clinical requirement for pancreatic enzyme replacement
  • Abnormal glucose tolerance defined by OGTT criteria for EGI, IGT, or CFRD, or diagnosed CFRD
  • There will be no restriction on enrollment of individuals with CFRD but without fasting hyperglycemia (fasting hyperglycemia is defined as fasting glucose ≥126 mg/dL); Individuals with CFRD and fasting hyperglycemia (defined as above or by the use of basal insulin therapy) must also have a HbA1c ≤8% and a random (non-fasting) C- peptide ≥1.2 ng/mL [15]
  • For females of reproductive potential: use of highly effective contraception method for the during of study participation; oral contraceptives, intra-uterine devices, Norplant®, Depo- Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable

Who cannot take part

  • Pulmonary exacerbation requiring IV antibiotics or systemic glucocorticoids within 4 weeks prior to randomization
  • Treatment with either CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, indinavir, ritonavir, saquinavir, telithromycin, boceprevir, nelfinavir, telaprevir, conivaptan, nefazodone, etc.) or inducers (e.g. phenobarbital, other barbiturates, carbamazepine, phenytoin, rifampicin, dexamethasone, etc.)
  • Use of herbal remedies, including St. John's Wort within 14 days prior to dosing
  • Change in CFTR modulator therapy in the previous 3 months
  • Prior lung, liver or another solid organ transplant
  • Established diagnosis of non-CF diabetes (e.g. type 1 diabetes)
  • History of clinically symptomatic pancreatitis within the last year
  • History of any illness or condition that, in the opinion of the investigator might confound the results of the study or pose an additional risk to the subject
  • Abnormal kidney function: creatinine >2x upper limit of normal (ULN) or potassium >5.5mEq/L on non-hemolyzed specimen
  • Abnormal liver function: persistent elevation of liver function tests >2.0 times ULN
  • Uncontrolled hyperlipidemia: triglycerides >500 or cholesterol >250 mg/dl
  • Hyperuricemia: serum uric acid >1.5 times ULN
  • Anemia: hemoglobin <10 g/dL
  • Pregnancy or lactation; a negative urine pregnancy test will be required at enrollment

Where in United States

  • Hospital of University of PennsylvaniaPhiladelphia, United StatesContact: Paola Alvarado, MSCRTaking people
  • University of Pennsylvania Center for Human Phenomic Science (CHPS)Philadelphia, United StatesContact: Paola Alvarado, MSCRTaking people

About the trial

What the trial wants to find out

This study is designed to determine the pharmacokinetic and pharmacodynamic response of dorzagliatin 50 mg twice daily following 7-day administration in individuals with pancreatic insufficient cystic fibrosis and abnormal glucose tolerance when compared to randomized, double-blind 7-day administration of placebo in a cross-over fashion. We hypothesize that dorzagliatin administration will result in significant drug concentrations and improved glucose tolerance, early-phase insulin secretion, glucagon suppression, and hepatic glycogen storage assessed during a standardized mixed-meal tolerance test.

The 2 groups in the trial

  • DorzagliatinTreatment being tested

    Dorzagliatin 50 mg orally twice daily for 7 days

    Treatment: Dorzagliatin and Placebo

  • PlaceboPlacebo, for comparison

    matched-placebo orally twice daily for 7 days

    Treatment: Dorzagliatin and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pharmacokinetic and Pharmacodynamic Effects of Dorzagliatin in Pancreatic Insufficient-Cystic Fibrosis: A Randomized Double-blind, Cross-over Trial
Plain-language title
Tests dorzagliatin for blood sugar problems in people with cystic fibrosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
31 August 2026